Anaphylaxis is the most severe clinical presentation of acute systemic allergic reactions. The occurrence of anaphylaxis has increased in recent years, and subsequently, there is a need to continue disseminating knowledge on the diagnosis and management, so every healthcare professional is prepared to deal with such emergencies. The rationale of this updated position document is the need to keep guidance aligned with the current state of the art of knowledge in anaphylaxis management. The World Allergy Organization (WAO) anaphylaxis guidelines were published in 2011, and the current guidance adopts their major indications, incorporating some novel changes. Intramuscular epinephrine (adrenaline) continues to be the first-line treatment for anaphylaxis. Nevertheless, its use remains suboptimal. After an anaphylaxis occurrence, patients should be referred to a specialist to assess the potential cause and to be educated on prevention of recurrences and self-management. The limited availability of epinephrine auto-injectors remains a major problem in many countries, as well as their affordability for some patients. 

过敏反应是急性全身过敏反应最严重的临床表现。近年来，过敏反应的发生率有所增加，随后，需要继续传播诊断和管理知识，因此每名医疗保健专业人员都准备应对此类紧急情况。本更新版立场文件的依据是需要使指南与过敏反应管理的当前最新知识保持一致。世界变态反应组织 (WAO) 过敏反应指南于2011年发表，目前的指南采用其主要适应症，纳入了一些新的变化。肌内注射肾上腺素（肾上腺素）仍然是过敏反应的一线治疗。然而，其使用仍然是次优的。发生过敏反应后，应将患者转诊至专科医生，以评估潜在原因，并接受预防复发和自我管理的教育。肾上腺素自动注射器的有限可用性仍然是许多国家的主要问题，也是一些患者的承受能力问题。